Biodesix

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biodesix reports robust Q4 revenue growth and expands reimbursement coverage

Biodesix's strong revenue growth and progress in reimbursement coverage underscore its position in the lung diagnostic testing market.
Continued success with newer tests like Nodify XL2 and Nodify CDT presents opportunities for further expansion and increased payer acceptance.

Biodesix reports robust Q1 revenue growth amidst operational challenges

Biodesix's Q1 2023 performance reflects strong revenue growth driven by core lung diagnostics and test volume expansion.
While facing challenges such as increased operating expenses and delayed clinical trials, the company maintains a focus on growth.
Opportunities lie in leveraging their precision tests portfolio, revenue diversification, and strategic investments for future growth.

Biodesix reports robust Q2 earnings, eyes sustained growth trajectory

Biodesix's Q2 2023 performance reflects strong revenue growth and improved margins, driven by core lung diagnostic tests.
While facing challenges in revenue diversification and cost management, the company's focus on clinical utility and growth opportunities remains promising.
With upcoming conference presentations and investor support, Biodesix is poised to sustain growth and advance towards profitability.

Biodesix reports robust Q3 earnings and strategic growth initiatives

Biodesix delivered a strong Q3 performance with revenue growth, improved margins, and cost management.
The company faces challenges in study timelines and commercialization but has opportunities in market expansion and product development.
By focusing on sales force expansion, quality culture, and cost control, Biodesix is positioning itself for future success.
Investors should note the company's resilience, growth potential, and strategic focus on profitability and market expansion.

Biodesix reports robust 2023 performance, eyes sustained growth in 2024

Biodesix's strong 2023 performance in revenue growth and margin improvement sets the stage for sustained growth in 2024.
The company's focus on operational efficiency, market expansion, and test adoption positions it well for future success.
Challenges in sustaining growth momentum and managing costs are balanced by opportunities in market penetration and profitability.
Investments in sales expansion and ongoing clinical studies present avenues for continued growth and innovation in the coming year.

Biodesix reports robust Q1 performance, focuses on growth strategies

Biodesix's Q1 2024 performance reflects strong revenue growth and operational achievements, despite a net loss.
Strategic partnerships and financial initiatives position the company well for future growth and innovation.
Addressing profitability challenges and operational efficiency will be key for Biodesix's sustained success in the competitive healthcare market.

Biodesix reports robust Q2 growth, raises revenue guidance for 2024

Biodesix's Q2 2024 performance reflects strong revenue growth and operational improvements, despite some profitability challenges.
The company's focus on innovation in lung cancer care and positive workplace culture position it well for future success.
With increased revenue guidance, expanding market opportunities, and a commitment to impact healthcare, Biodesix shows promise for continued growth.

Biodesix reports robust Q3 performance amidst revenue growth challenges

Biodesix demonstrated strong financial performance in Q3 2024 with revenue growth, improved margins, and a focus on innovation.
While facing challenges in biopharma services revenue and operational disruptions, the company remains resilient and proactive.
Opportunities lie in revenue growth through lung volume increase, addressing payment issues, and expanding sales team effectiveness.
Overall, Biodesix's strategic focus on growth and efficiency positions it well for future success in the diagnostics market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

BOULDER, Colo. & SAN FRANCISCO--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share health data. Through this partnership, Biodesix will anonymize the lung cancer portion of their expansive sample and data biobank using Datavant's proprietary tokenization process and

Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank

The stock price of Biodesix, Inc. (Nasdaq: BDSX) increased by over 8% pre-market. This is why it happened.

BDSX Stock Price: Over 8% Increase Pre-Market Explanation

First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021. William Blair 41st Annual Growth Stock Conference Date: Wednesday, June 2, 2021 Time: 2:00 PM CT The presentation will be webcast live and available for replay under “News & Ev

Biodesix to Present at the William Blair 41st Annual Growth Stock Conference

Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2021 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the first quarter ended March 31, 2021 and provided a corporate update. “We were pleased with our strong operating and financial performance in the first quarter and believe we are off to a solid start in 2021,” said Scott Hutton, Chief Executive Officer. “We are encouraged by the trends in our core l

Biodesix Announces First Quarter 2021 Results

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add a blood-based 52-gene next generation sequencing (NGS) test to their portfolio of molecular testing based on a recent publication. Of critical importance, the publication, “Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC,” in Diagnostics showed that the rapid liquid biopsy testing wa

Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership with GenScript Biotech Corporation, a webinar to present novel data on the rapid detection of total SARS-CoV-2 neutralizing antibodies using cPass™ technology. Neutralizing antibodies may specifically block the interaction between the receptor binding protein on SARS-CoV-2, and the host cell's membrane receptor protein, t

Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Dial-in and call details are as f

Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021

BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Pulmonary disease expert, Dr. Susan Garwood, is hosted by CHEST to discuss standardized risk assessment to inform lung nodule management

Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management

BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Biodesix releases new data at AACR annual meeting on the use of proteomic profiling to help guide physician treatment strategies for NSCLC patients.

Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC Patients

BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Biodesix receives two important U.S. patents for diagnostic methods, which seek to improve care for cancer patients.

Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix announces the closing of a $30 million term loan.

Biodesix Announces Closing of New $30 Million Term Loan

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix releases fourth quarter and full year 2020 results

Biodesix Announces Fourth Quarter and Full Year 2020 Results

BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Dial-in and call d

Biodesix to Report Fourth Quarter and Fiscal 2020 Financial Results on March 16, 2021

BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021. The Healthcare Technology Report noted that the past twelve months, more than any other period in recent history, have showcased the outstanding talent, ingenuity, and determination of the world's leading bio

Biodesix CEO Scott Hutton Selected as One of Top 25 Biotech CEOs of 2021

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company has partnered with Chicago Public Schools (CPS) to provide antigen and Droplet Digital PCR (ddPCR)™ testing for Chicago Public School teachers and staff. The CPS testing program, which launched in January, is a surveillance testing protocol and uses rapid antigen tests to monitor the prevalence of COVID-19 among asympto

Biodesix Partners with Chicago Public Schools for COVID-19 Testing to Safely Reopen Schools

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precision Oncology Day, which is being held February 17, 2021. Event Details: Event:     BTIG Virtual MedTech, Digital

Biodesix to Participate in Two February Conferences

BOULDER, Co.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development of a new AI-based COVID-19 algorithm and the important data from a related study. The paper, entitled, “Predicting Prognosis in COVID-19 Patients using Machine Learning and Readily Available Clinical Data,” demonstrates the AI-based algorithm's ability to rapidly and accurately help physicians pred

Biodesix Publishes Data on New COVID-19 Artificial Intelligence (AI)-Based Algorithm for Use in Clinical Decision Support Systems

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton was selected as the CEO of the Year, 2020 – The USA by CEO Monthly. The magazine seeks to honor CEOs whose commitment to promoting business excellence, determination and innovative approaches help them take a business to the next level. Hutton was selected from a wide range of nominees for his r

Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings from these recent studies demonstrate that an individual patient's immune profile can provide information to suppor

Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX) today announced an agreement with HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs. Terms of the partnership were not disclosed. Biodesix leverages multiple technologies with its proprietary artifici

HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization

Allegro MicroSystems

Atea Pharmaceuticals

Gatos Silver

Galecto

Leslie's

Lufax Holding

MediaAlpha

Root

SQZ Biotechnologies

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 million at a $4.4 billion market cap.

U.S. IPO Week Ahead: The IPO Market Takes A Break During The Shortened Holiday Week

Biodesix has gone public in an offering which was not well-received by the market. Lack of growth and steep losses make investors rightfully cautious based on the conditions as they are today.

News for Biodesix Stock (BDSX)